Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,342
Distinct drugs
373
Records naming a cancer
982
Dated in the last 12 months
177
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 42 | Sep 22, 2026 |
| EMA | EU | 461 | 246 | 386 | 75 | 20 | Sep 18, 2026 |
Data updated 2 days agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 23, 2012 | Vandetanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as CAPRELSA (DIN 02378582) under ATC L01EX04 VANDETANIB. Indications are not published in the Drug Product Database —… | DIN02378582 | approvedsource: Marketed | health-canada-dpd |
| Feb 17, 2012 | Vemurafenib | EMA EU | Melanoma | Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic… | centralisedEMEA/H/C/002409 | approved | ema |
| Feb 16, 2012 | Vandetanib | EMA EU | Thyroid Gland Medullary Carcinoma | Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally… | centralisedEMEA/H/C/002315 | approved | ema |
| Feb 7, 2012 | Mitomycin | FDA US | cancer not stated in this record | Mitosol ® is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery. Mitosol ® is an antimetabolite indicated as… | ORIGNDA022572 | approved | openfda |
| Feb 3, 2012 | Thalidomide | FDA US | cancer not stated in this record | Efficacy supplement 2012-02-03 (see label) | SUPPLNDA020785 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2012 | Docetaxel | EMA EU | cancer not stated in this record | Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 22, 2011 | Topotecan | EMA EU | cancer not stated in this record | Topotecan monotherapy is indicated for the treatment of patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the… |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 23, 2011 | Bicalutamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as AVA-BICALUTAMIDE (DIN 02360993) under ATC L02BB03 BICALUTAMIDE. Indications are not published in the Drug Product… | DIN02360993 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Oct 8, 2011 | Leuprolide | FDA US | cancer not stated in this record | Efficacy supplement 2011-10-08 (see label) | SUPPLNDA020263 | approved | openfda |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 30, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP-LETROZOLE (DIN 02373009) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02373009 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 31, 2011 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02370034) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02370034 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| centralisedEMEA/H/C/002317 |
| withdrawnsince Jan 31, 2015 |
| ema |
| Jan 31, 2012 | Imatinib Mesylate | FDA US | cancer not stated in this record | Efficacy supplement 2012-01-31 (see label) | SUPPLNDA021588 | approved | openfda |
| Jan 31, 2012 | Imatinib | FDA US | cancer not stated in this record | Efficacy supplement 2012-01-31 (see label) | SUPPLNDA021588 | approved | openfda |
| Jan 30, 2012 | Vismodegib | FDA US | Basal Cell Carcinoma | ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that… | ORIGNDA203388 | approved | openfda |
| Jan 27, 2012 | Axitinib | FDA US | cancer not stated in this record | in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. | ORIGNDA202324 | approved | openfda |
| Jan 27, 2012 | Axitinib | FDA US | Renal Cell Carcinoma | as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. | ORIGNDA202324 | approved | openfda |
| Jan 27, 2012 | Axitinib | FDA US | Renal Cell Carcinoma | in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). | ORIGNDA202324 | approved | openfda |
| Jan 23, 2012 | Bortezomib | FDA US | cancer not stated in this record | Efficacy supplement 2012-01-23 (see label) | SUPPLNDA021602 | approved | openfda |
| Jan 12, 2012 | Pazopanib | FDA US | cancer not stated in this record | Efficacy supplement 2012-01-12 (see label) | SUPPLNDA022465 | approved | openfda |
| centralisedEMEA/H/C/002261 |
| withdrawnsince Oct 2, 2014 |
| ema |
| Dec 21, 2011 | Lenalidomide | FDA US | cancer not stated in this record | Efficacy supplement 2011-12-21 (see label) | SUPPLNDA021880 | approved | openfda |
| Dec 13, 2011 | 5-Aminolevulinic Acid | EMA EU | cancer not stated in this record | Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field… | centralisedEMEA/H/C/002204 | approved | ema |
| withdrawnsource: Cancelled Post Marketsince Aug 21, 2014 |
| health-canada-dpd |
| Nov 18, 2011 | Aflibercept | FDA US | cancer not stated in this record | EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related… | ORIGBLA125387 | approved | openfda |
| Nov 18, 2011 | Ibritumomab Tiuxetan | FDA US | cancer not stated in this record | Efficacy supplement 2011-11-18 (see label) | SUPPLBLA125019 | approved | openfda |
| Nov 18, 2011 | Pemetrexed | FDA US | cancer not stated in this record | Efficacy supplement 2011-11-18 (see label) | SUPPLNDA021462 | approved | openfda |
| Nov 18, 2011 | Nilotinib | FDA US | cancer not stated in this record | Efficacy supplement 2011-11-18 (see label) | SUPPLNDA022068 | approved | openfda |
| Nov 16, 2011 | Ruxolitinib | FDA US | cancer not stated in this record | intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential… | ORIGNDA202192 | approved | openfda |
| Nov 16, 2011 | Ruxolitinib | FDA US | Polycythemia Vera | polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. | ORIGNDA202192 | approved | openfda |
| Nov 7, 2011 | Cetuximab | FDA US | cancer not stated in this record | Efficacy supplement 2011-11-07 (see label) | SUPPLBLA125084 | approved | openfda |
| Nov 1, 2011 | Bortezomib | FDA US | cancer not stated in this record | Efficacy supplement 2011-11-01 (see label) | SUPPLNDA021602 | approved | openfda |
| Oct 4, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as TARO-LETROZOLE (DIN 02372282) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02372282 | withdrawnsource: Cancelled Post Marketsince Nov 22, 2022 | health-canada-dpd |
| withdrawnsource: Dormantsince Aug 3, 2026 |
| health-canada-dpd |
| Sep 30, 2011 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as METHOTREXATE INJECTION BP (DIN 02327236) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02327236 | approvedsource: Marketed | health-canada-dpd |
| Sep 29, 2011 | Cisplatin | Health Canada CA | cancer not stated in this record | Marketed in Canada as CISPLATIN INJECTION BP (DIN 02366711) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product… | DIN02366711 | withdrawnsource: Cancelled Post Marketsince Jul 25, 2022 | health-canada-dpd |
| Sep 29, 2011 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2011-09-29 (see label) | SUPPLBLA103964 | approved | openfda |
| Sep 8, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as MYL-LETROZOLE (DIN 02372169) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database… | DIN02372169 | withdrawnsource: Cancelled Post Marketsince Jun 28, 2016 | health-canada-dpd |
| Sep 5, 2011 | Abiraterone | EMA EU | Castration-Resistant Prostate Carcinoma | Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who… | centralisedEMEA/H/C/002321 | approved | ema |
| Sep 2, 2011 | Everolimus | EMA EU | cancer not stated in this record | Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Votubia is indicated for the treatment of adult patients with renal… | centralisedEMEA/H/C/002311 | approved | ema |
| Sep 2, 2011 | Dasatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as SPRYCEL (DIN 02360810) under ATC L01EA02 DASATINIB. Indications are not published in the Drug Product Database — see… | DIN02360810 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Cancelled Post Marketsince Oct 28, 2025 |
| health-canada-dpd |
| Aug 31, 2011 | Gemcitabine | Health Canada CA | cancer not stated in this record | Marketed in Canada as GEMCITABINE FOR INJECTION (DIN 02324202) under ATC L01BC05 GEMCITABINE. Indications are not published in the Drug… | DIN02324202 | withdrawnsource: Cancelled Post Marketsince Jan 17, 2020 | health-canada-dpd |
| Aug 29, 2011 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as LETROZOLE (DIN 02348896) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02348896 | withdrawnsource: Cancelled Post Marketsince Jun 25, 2014 | health-canada-dpd |
| Aug 26, 2011 | Crizotinib | FDA US | cancer not stated in this record | XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose… | ORIGNDA202570 | approved | openfda |
| Aug 26, 2011 | Crizotinib | FDA US | Anaplastic Large Cell Lymphoma | o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic… | ORIGNDA202570 | approved | openfda |
| Aug 26, 2011 | Crizotinib | FDA US | Anaplastic Large Cell Lymphoma | pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL)… | ORIGNDA202570 | approved | openfda |
| Aug 23, 2011 | Cabazitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as JEVTANA (DIN 02369524) under ATC L01CD04 CABAZITAXEL. Indications are not published in the Drug Product Database —… | DIN02369524 | withdrawnsource: Cancelled Post Marketsince Dec 13, 2023 | health-canada-dpd |
| Aug 22, 2011 | Peginterferon Alfa-2a | FDA US | cancer not stated in this record | Efficacy supplement 2011-08-22 (see label) | SUPPLBLA103964 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | cancer not stated in this record | Efficacy supplement 2011-08-19 (see label) | SUPPLBLA125388 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | cancer not stated in this record | . • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell… | ORIGBLA125388 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | Systemic Anaplastic Large Cell Lymphoma | . • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen | ORIGBLA125388 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | Classic Hodgkin Lymphoma | . • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent… | ORIGBLA125388 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | Classic Hodgkin Lymphoma | . • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell… | ORIGBLA125388 | approved | openfda |
| Aug 19, 2011 | Brentuximab Vedotin | FDA US | Classic Hodgkin Lymphoma | . • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with… | ORIGBLA125388 | approved | openfda |